Heilongjiang ZBD Pharmaceutical Co., Ltd. Share Price

Equities

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 28/04/2024 BST 5-day change 1st Jan Change
12 CNY +5.36% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. +9.59% -1.32%

Financials

Sales 2022 4.21B 582M 46.39B Sales 2023 3.14B 434M 34.6B Capitalization 11.42B 1.58B 126B
Net income 2022 185M 25.54M 2.04B Net income 2023 473M 65.31M 5.21B EV / Sales 2022 3.29 x
Net Debt 2022 1.86B 258M 20.53B Net Debt 2023 1.7B 234M 18.67B EV / Sales 2023 4.17 x
P/E ratio 2022
64.8 x
P/E ratio 2023
24.2 x
Employees 2,760
Yield 2022
0.22%
Yield 2023
-
Free-Float 23.66%
More Fundamentals * Assessed data
Dynamic Chart
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies MT
More news
1 day+5.36%
1 week+9.59%
Current month+14.29%
1 month+14.29%
3 months+9.49%
6 months-6.32%
Current year-1.32%
More quotes
1 week
10.83
Extreme 10.83
12.06
1 month
10.45
Extreme 10.45
12.06
Current year
8.89
Extreme 8.89
12.50
1 year
8.89
Extreme 8.89
17.87
3 years
8.89
Extreme 8.89
19.22
5 years
8.89
Extreme 8.89
19.22
10 years
8.89
Extreme 8.89
60.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 31/12/16
Founder 61 27/10/96
Director of Finance/CFO 43 25/09/19
Members of the board TitleAgeSince
Director/Board Member 60 16/05/19
Founder 61 27/10/96
Chairman 51 31/12/02
More insiders
Date Price Change Volume
29/04/24 12 +5.36% 10,378,890
26/04/24 11.39 +2.34% 7,240,800
25/04/24 11.13 +1.92% 6,655,239
24/04/24 10.92 -2.85% 7,485,568
23/04/24 11.24 +2.65% 5,972,801

End-of-day quote Shanghai S.E., April 28, 2024

More quotes
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603567 Stock